38289-20-2

Basic information

• Product Name: Cyclohexanecarboxylic acid, 5-cyano-2-oxo-5-phenyl-, Methyl ester
• Synonyms: Methyl 5-cyano-2-oxo-5-phenylcyclohexanecarboxylate;Cyclohexanecarboxylic acid, 5-cyano-2-oxo-5-phenyl-, Methyl ester
• CAS NO: 38289-20-2
• Molecular Formula: C₁₅H₁₅NO₃
• Molecular Weight: 257.2845
• Mol File: 38289-20-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Cyclohexanecarboxylic acid, 5-cyano-2-oxo-5-phenyl-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 5-cyano-2-oxo-5-phenyl-, Methyl ester(38289-20-2)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 5-cyano-2-oxo-5-phenyl-, Methyl ester(38289-20-2)

Safety Data

• Hazardous Substances Data: 38289-20-2(Hazardous Substances Data)

Upstream product

• 38289-18-8 dimethyl 4-cyano-4-phenylheptanedioate 
• 140-29-4 phenylacetonitrile 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 37563-99-8 4-cyano-4-phenyl-heptanedioic acid 
• 25115-74-6 4-cyano-4-phenylcyclohexanone 
• 25163-93-3 8-phenyl-1,4-dioxaspiro[4,5]decane 
• 51509-98-9 8-Phenyl-1,4-dioxaspiro<4.5>decan-8-carbonitril 
• 4894-75-1 1-phenyl-4-cyclohexanone 
• 38289-22-4 cis-4-hydroxy-1-phenylcyclohexanecarbonitrile 

Relevant articles and documents

Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives

Malaria remains one of the deadliest infectious diseases worldwide and continues to infect hundreds of millions of individuals each year. Here we report the discovery and derivatization of a series of 2,6-dibenzylidenecyclohexanones targeting the chloroquine-sensitive 3D7 strain of Plasmodium falciparum. While the initial lead compound displayed significant toxicity in a human cell proliferation assay, we were able to identify a derivative with no detectable toxicity and sub-micromolar potency.

Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors

The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models.

Spirocyclic Azaindole Derivatives

The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments.